| Characteristics |
Median (range) |
Number (%) |
| Age |
71 (53-82) |
|
|
Stage |
|
|
| cT1c |
|
3 (15) |
| cT2 |
|
6 (30) |
| cT3 |
|
11 (55) |
| cN0 cM0 |
|
20 (100) |
| |
|
|
| PSA (ng/ml) |
13.8 (4.1-38.0) |
|
|
Gleason score |
|
|
| 5-6 |
|
12 (60) |
| 7 |
|
6 (30) |
| 8-10 |
|
2 (10) |
|
Total dose of RT(Gy) |
76.7 (74.0-80.4) |
|
|
Pelvic nodes irradiation |
|
13 (41) |
|
Brachytherapy boost |
|
5 (25) |
|
Androgen deprivation |
|
14 (70) |
|
Years between treatment and imaging |
6.5 (5.2-8.9) |
|
|
PSA at imaging study (ng/ml) |
0.25 (<0.04-0.45) |
|
| PSA at last follow-up (ng/ml) |
0.27 (<0.04-1.39) |
|
|
